Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease

Phase: 2b

Status: Ongoing

Details

PTK0796-NTM-20203 – A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc)

Sponsor: Paratek

NCT04922554 - IRB#2021-026

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top